Sei Investments Co. Has $6.57 Million Stock Position in Moderna, Inc. $MRNA

Sei Investments Co. raised its stake in Moderna, Inc. (NASDAQ:MRNA) by 76.2% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 129,395 shares of the company’s stock after acquiring an additional 55,939 shares during the period. Sei Investments Co.’s holdings in Moderna were worth $6,573,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. MUFG Securities EMEA plc bought a new stake in shares of Moderna during the second quarter worth $28,000. Flagship Harbor Advisors LLC bought a new position in Moderna during the 4th quarter worth about $31,000. Canton Hathaway LLC acquired a new stake in shares of Moderna in the 1st quarter valued at about $31,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Moderna by 148.3% in the second quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock valued at $37,000 after purchasing an additional 801 shares in the last quarter. Finally, Assetmark Inc. grew its holdings in shares of Moderna by 35.1% during the first quarter. Assetmark Inc. now owns 801 shares of the company’s stock worth $41,000 after buying an additional 208 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Stock Performance

Moderna stock opened at $55.14 on Tuesday. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $85.60. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. The stock has a market cap of $21.88 billion, a PE ratio of -6.90 and a beta of 0.91. The business’s 50-day moving average price is $59.54 and its two-hundred day moving average price is $52.75.

Moderna (NASDAQ:MRNA) last posted its earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, topping the consensus estimate of ($2.03) by $0.06. The business had revenue of $145.00 million for the quarter, compared to the consensus estimate of $102.93 million. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The firm’s revenue was up 2.1% compared to the same quarter last year. During the same period last year, the company earned ($2.13) EPS. As a group, analysts expect that Moderna, Inc. will post -6.41 earnings per share for the current fiscal year.

Analysts Set New Price Targets

MRNA has been the subject of a number of recent research reports. Bank of America upped their price target on Moderna from $34.00 to $38.00 and gave the stock an “underperform” rating in a research report on Tuesday, July 7th. The Goldman Sachs Group boosted their price target on shares of Moderna from $49.00 to $67.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Moderna in a research report on Friday, June 12th. Royal Bank Of Canada increased their price target on Moderna from $38.00 to $45.00 and gave the company a “sector perform” rating in a research report on Tuesday, July 7th. Finally, UBS Group reiterated an “overweight” rating on shares of Moderna in a research note on Monday. Three investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and five have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus price target of $42.13.

Insiders Place Their Bets

In other news, President Stephen Hoge sold 53,336 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $51.37, for a total value of $2,739,870.32. Following the completion of the sale, the president owned 1,483,848 shares of the company’s stock, valued at approximately $76,225,271.76. This represents a 3.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $50.00, for a total value of $173,550.00. Following the completion of the sale, the insider owned 67,468 shares in the company, valued at $3,373,400. The trade was a 4.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 119,406 shares of company stock valued at $5,928,762. 10.80% of the stock is currently owned by company insiders.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.